CD Genomics, a leader in sequencing, microarray analysis, library construction and genotyping, recently announced availability of its CDAMP® SARS-CoV-2 Panel Kit, CDCAP® β-CoVs Panel Kit and CDCAP® Respiratory Virus Panel Kit for SARS-CoV-2 detection and research via its predesigend NGS panels. The highly multiplexed target enrichment kit covers the entire genome of the SARS-CoV-2 virus that is the cause of the global COVID-19 pandemic, enabling complete genome sequencing and epidemiological studies of this dangerous new pathogen.
The novel Coronavirus pandemic has gathered a quick response from the viral research and therapeutics community around the world. The researchers need robust and reliable genomic tools to classify and characterize viral samples, and genome engineering tools to build effective vaccines to help stop the spread of this virus.
CD Genomics chief scientist commented, “It is important for researchers to learn more about the SARS-CoV-2 virus, and companies like us shoulder the responsibility to mount predominant campaigns to treat and prevent it. Our CDAMP® and CDCAP® target enrichment technology is a preferred solution to support this effort. It greatly facilitates genomic studies of the virus, such as SARS-CoV-1, MERS-CoV, SARS-CoV-2, influenza A/B/C virus, etc. rapidly converting viral RNA into sequencing-ready libraries in a few hours’ time using a streamlined, efficient and cost-effective workflow that works well with low viral loads. Even with rapid mutations, our new panels provide high coverage of target regions to provide sensitive detection. Through sequencing, these mutations can also be tracked to study the path of infection and examine different strains.”
CD Genomics’ panels are a series of proprietary, ultra-high multiplexed NGS target enrichment technology that integrates the company’s advanced panel design algorithms (multiplexed target enrichment and hybridization capture-based target enrichment). These panels are featured in innovative background cleaning technique that allows plenty of amplicons to be multiplexed in a single reaction pool, allowing a large number of targets to be interrogated in a single assay, which is designed as ready-to-use panels or as customized assays and optimized using.
Versions of the panels are available for various respiratory disease-related viruses, such as SARS-CoV-1, MERS-CoV, SARS-CoV-2, influenza A/B/C virus, etc.
Here is a brief list:
CDAMP® SARS-CoV-2 Panel Kit
CDCAP® β-CoVs Panel Kit
CDCAP® Respiratory Virus Panel Kit
For more information on the CD Genomics SARS-CoV-2 Panels, visit the website.
Note: The Panels are for Research Use Only. Not intended for disease diagnosis.
